<DOC>
	<DOCNO>NCT01984489</DOCNO>
	<brief_summary>SHR117887 new dipeptidyl peptidase ( DPP ) -4 inhibitor . This study aim evaluate efficacy safety SHR117887 combination therapy Metformin patient Type 2 Diabetes Metformin monotherapy Who Inadequate Glycemic Control</brief_summary>
	<brief_title>Efficacy Safety Study SHR117887 Combination With Metformin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients diagnose type 2 diabetes mellitus Patients treat metformin least 8 week stable dose least 1500mg daily prior screen visit HbA1C：≥7.5 % ≤11.0 % screeing visit end runin period Age : ≥20 ≤70 year BMI ( body mass index ) : ≥20 ≤35 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>SHR117887 , Metformin , combination , PhaseII</keyword>
</DOC>